urogenital cancer
Natera, Alliance for Clinical Trials in Oncology Partner for Urothelial Cancer Study
The study will assess the use of Natera's Signatera assay in guiding treatment among people with muscle-invasive urothelial cancer after bladder removal.
Akoya Biosciences, Acrivon Therapeutics Partner to Develop CDx
The companies will codevelop, validate, and commercialize a companion diagnostic for Acrivon's targeted DNA damage response inhibitor therapy, ACR-368.
Kinnate Doses First Patient in Phase I Trial of FGFR Inhibitor
With KIN-3248, Kinnate aims to overcome acquired resistance to FGFR inhibitors in patients with bile duct cancer and urothelial cancer bearing alterations in FGFR2 and FGFR3.
InnoCare Begins ICP-192 Study in US in FGFR-Altered Cancers
The pan-FGFR inhibitor is also being studied in China in FGFR-aberrant, advanced cholangiocarcinoma and urothelial cancers.
Kura Oncology Sees Proof of Tipifarnib Activity in HRAS-Mutated Urothelial Cancer
Out of 13 evaluable patients in the Phase II study, five saw their tumors shrink and four experienced progression-free survival for more than six months.